Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences reported proposed insider sales under Form 144. The filing lists multiple equity compensation-based disposals and notices of proposed sales dated 02/25/2026, 03/02/2026, and 04/02/2026 by Donald E. Bobo Jr., with share quantities and aggregate dollar amounts shown.
Edwards Lifesciences CEO Bernard J. Zovighian reported several stock transactions. On May 11, 2026, he exercised 47,207 Performance Rights into common stock, with 26,198 shares withheld at $79.96 per share to cover tax obligations, leaving him with additional net shares rather than an open-market sale. The filing notes these vested from performance-based restricted stock units granted in May 2023, after the board’s committee certified 167.70% of the target as earned.
On May 12, 2026, a trust associated with him sold a total of 36,351 common shares in open-market trades at weighted average prices around $78 per share, and there were two bona fide gifts totaling 53,280 shares between direct and trust holdings. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025. After the reported transactions, he holds about 99,165 shares directly, plus additional indirect holdings through a trust and a 401(k) plan.
Edwards Lifesciences Corp corporate officer Donald E. Bobo Jr. reported equity compensation activity tied to performance-based restricted stock units. On May 11, 2026, he exercised 13,457 Performance Rights, receiving the same number of shares of common stock.
To cover tax obligations, 7,469 common shares were withheld at $79.96 per share, a non-market disposition. After these transactions, he held 40,235.2532 common shares directly, plus 121,756 shares by trust and 38,969.5756 shares in a 401(k) indirectly. A prior grant from May 11, 2023 vested at 167.70% of its target following a three-year performance period, and the related Performance Rights now show 0 remaining, having been fully exercised.
Edwards Lifesciences Corp executive Daveen Chopra reported routine equity compensation activity involving performance-based restricted stock units. Chopra exercised performance rights covering 13,583 shares of common stock, linked to awards granted on May 11, 2023 with three-year performance vesting.
In connection with vesting, 7,538 shares of common stock were disposed of to cover tax obligations at a price of $79.96 per share, rather than through an open-market sale. Following these transactions, Chopra holds 45,824 shares of Edwards Lifesciences common stock directly.
The board’s Compensation and Governance Committee previously determined that 167.70% of the target number of performance-based units would vest as of May 11, 2026, and this Form 4 reflects the resulting share delivery and tax-withholding disposition.
Edwards Lifesciences Corporation submitted a Form 144 notice reporting proposed sales tied to recent equity-compensation vesting events. The filing lists restricted stock lapses on 05/03/2026 (523 shares), 05/07/2026 (4,222 shares), 05/08/2026 (5,489 shares) and a PSU/RSU entry on 05/11/2026 (26,640 shares). The filing also records a prior sale of 22,430 shares for $1,719,742.00 on 02/12/2026.
Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem reported compensation-related equity transactions tied to performance-based restricted stock units. On May 11, 2026, he exercised 19,830 Performance Rights into the same number of common shares following the Compensation and Governance Committee’s decision that 167.70% of the target units would vest.
To cover tax obligations, 11,004 common shares were disposed of through a tax-withholding transaction at $79.96 per share, rather than via an open-market sale. After these transactions, he directly holds 46,740 common shares and indirectly holds 266,318 common shares through a trust. The Performance Rights exercised in this filing are now fully converted, with no remaining derivative position from this award.
Edwards Lifesciences Corp executive Wayne Markowitz, CVP, JAPAC, reported a mix of share sales and new equity awards. He completed an open-market sale of 593 shares of common stock at $79.73 per share on May 11, 2026, and held 21,679.8708 shares afterward.
On May 7, 2026, he received 5,200 restricted stock units and separate 5,200 performance-based restricted stock units under the Long-Term Stock Incentive Compensation Program, plus 26,400 employee stock options with a $82.76 exercise price, all vesting in installments starting one year after grant.
On May 7 and May 8, a total of 490 shares of common stock were disposed of as tax-withholding transactions related to equity compensation, rather than open-market sales.
Edwards Lifesciences CEO Bernard J. Zovighian reported multiple equity compensation and routine share transfers. On May 7, 2026, he received 43,800 restricted stock units and 43,800 performance-based stock units under the company’s Long-Term Stock Incentive Compensation Program, plus options for 245,300 shares of common stock at an exercise price of $82.76 per share.
The time-based restricted stock units are scheduled to vest in four equal annual installments starting one year after grant, while the performance units are scheduled to vest on May 7, 2029 based on three-year performance goals. On the same date, options are scheduled to vest in 36 approximately equal monthly installments beginning one month after grant.
He also reported bona fide gifts totaling 19,422 shares and tax-withholding dispositions totaling 9,551 shares between May 7–11, 2026. After these transactions, he holds 104,795.6499 shares directly, 21,750.5511 shares indirectly through a trust, and 3,733.5603 shares indirectly via a 401(k) plan.
Edwards Lifesciences Corp executive Daniel J. Lippis reported a small tax-related share disposition. On May 11, 2026, 362 shares of common stock were disposed of at $79.96 per share to cover tax obligations. After this non-market transaction, he directly holds about 40,410.91 shares.
Edwards Lifesciences Corporation submitted a Rule 144 notice reporting proposed transactions in Common stock. The form lists 47,280.00 (reported figure) and a separate numeric entry 575,800,000. It also shows restricted stock lapse events of 19 shares on 05/07/2025 and 574 shares on 05/07/2026.